NCT00433095View on ClinicalTrials.gov

Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer

PHASE2CompletedINTERVENTIONAL

Timeline

Start Date

Not specified

Conditions

Carcinoma Breast Stage IV

Interventions

DRUG

Navelbine

DRUG

Herceptin

DRUG

Navelbine (oraly)

Trial Locations (1)

81377

University of Munich - Klinikum Grosshdern, Munich

Sponsors

Collaborators (1)

Pierre Fabre Laboratories

All Listed Sponsors

collaborator

Pierre Fabre Laboratories

INDUSTRY

lead

Ludwig-Maximilians - University of Munich

OTHER

NCT00433095 - Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer | Biotech Hunter | Biotech Hunter